PACB Pacific Biosciences of California Inc

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS). This collaboration aims to accelerate cancer research by leveraging PacBio's advanced sequencing technologies, including the innovative Onso short-read sequencing platform, to profile the genomic landscape of prevalent cancers in Asia.

The research project will focus on profiling prevalent cancers in Asia using PacBio’s Onso short-read sequencing system and Kinnex long-read sequencing kit, with a particular emphasis on single-cell RNA sequencing. The Onso platform, known for its exceptional accuracy in short-read sequencing, will enable researchers to detect clinically relevant mutations across various cancer types, such as gastrointestinal stromal tumors (GIST). Its unique ability to deliver highly accurate data at scale makes it ideal for exploring genomic variants in cancer samples, ensuring robust analysis that could ultimately provide better cancer diagnostics and therapeutics.

As part of the collaborative effort, PacBio’s authorized channel partner in Asia, DKSH, has installed the Onso platform at the Cancer Discovery Hub in NCCS, which is dedicated to expanding cancer research and discovery. The findings from this collaboration are expected to benefit not only Singapore but also provide access to this cutting-edge technology to the broader research community in Asia. The collaboration with DKSH strengthens PacBio’s commitment to supporting local researchers in advancing cancer genomics in the region.

In combination with Revio's long-read sequencing capabilities, this research collaboration will allow scientists to conduct comprehensive multi-omics studies, analyzing transcript isoforms and genetic variants at the single-cell level. The integration of Onso for short reads and Revio for long reads ensures a complete and in-depth analysis of the cancer genome, offering new possibilities for precision oncology.

Asst Prof Jason Chan, Director of the Cancer Discovery Hub at NCCS, said: “We are excited to collaborate with PacBio on this initiative which combines the power of short-read and long-read sequencing, allowing us to delve deeper into the genomic complexities of cancers prevalent in Asia. The ultimate aim is to improve tailored diagnostic and treatment options for our patients.”

Jason Kang, General Manager and Vice President of PacBio APAC, commented, “At PacBio, we are committed to pushing the boundaries of cancer research with our cutting-edge sequencing platforms. With the installation of the Onso platform, enabled by our trusted partner DKSH, we are bringing our advanced sequencing solutions closer to the research community, empowering researchers to unlock new insights into cancer biology.”

For more information, please contact:

Contacts (PacBio)

Investors: Todd Friedmanir@pacificbiosciences.com

Media:pr@pacificbiosciences.com

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including in connection with the RCA between PacBio and NCCS; unlocking Onso’s potential; accelerating breakthroughs in cancer genomics research; genomic landscape profiling of prevalent cancers; detection of clinically-relevant mutations; expectations that the collaboration will benefit the Singapore and Asian research communities; conducting comprehensive multi-omics studies, and ensuring complete and in-depth analysis of the cancer genome, using Revio and Onso platforms; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in sequencing a large number of genomes, and the difficulty of generating discoveries across various areas of research; potential product performance and quality issues; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with international operations. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.